Regeneron to Report Fourth Quarter and Full Year 2017 Financial and Operating Results and Host Conference Call and Webcast on February 8, 2018
- Nasdaq 100 futures hit record high ahead of business activity data
- Bitcoin (BTC) Recovers to $34,000 as Analysts Insists Crypto Winter Won't Repeat Again
- Cyclical currencies lead after dust settles on Fed
- Xpeng (XPEV) Leaps After Receiving a Green Light From Regulators to Raise Up To $2 Billion in Hong Kong IPO
- 'A Stampede for Clean Energy': Amazon (AMZN) Commits to Buy More Renewable Energy, Becomes the Top All-Time US Corporate Buyer
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
TARRYTOWN, N.Y., Jan. 23, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2017 financial and operating results on Thursday, February 8, 2018, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Conference Call InformationTo access this call, dial (800) 708-4539 (U.S.) or (847) 619-6396 (International). A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at www.regeneron.com. A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.
About RegeneronRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, Regeneron's unique ability to consistently translate science into medicine has led to six FDA-approved treatments and numerous product candidates, all of which were homegrown in its laboratories. Regeneron's medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies, including VelocImmune® to yield optimized fully-human antibodies, and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Manisha Narasimhan, Ph.D.
View original content:http://www.prnewswire.com/news-releases/regeneron-to-report-fourth-quarter-and-full-year-2017-financial-and-operating-results-and-host-conference-call-and-webcast-on-february-8-2018-300586890.html
SOURCE Regeneron Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regeneron to Participate in Guggenheim Biopharma Strategy Series
- Seaspan Announces Two 12,000 TEU Containership Newbuilds
- Carrols Restaurant Group, Inc. Announces Offering of Senior Notes
Create E-mail Alert Related CategoriesPress Releases
Related EntitiesTwitter, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!